參考文獻(xiàn)/References:
[1] Diamantis I T, Fabio B, Kota S, et al.Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification [J].Ann Surg Oncol, 2019 26(11):3693-3700.
[2] Marlène P, Régis V, Céline F, et al.Stability of peptides and therapeutic success in cancer [J].Expert Opin Drug Metab Toxicol, 2011, 7(7):793-802.
[3] 陳小元, 18F-阿法肽的基礎(chǔ)研發(fā)及臨床轉(zhuǎn)化歷程 [J].中華核醫(yī)學(xué)與分子影像雜志, 2019, 39 (4): 193-195.
[4] Fei L, Teng C, Qingjian D, et al.Evaluation of (99m)Tc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT [J].Nucl Med Biol, 2015, 42(3):256-262.
[5] Yesen L, Deliang Z,Ying S, et al.Syntheses and preliminary evaluation of [(18) F]AlF-NOTA-G-TMTP1 for PET imaging of high aggressive hepatocellular carcinoma [J].Contrast Media Mol Imaging, 2016, 11(4):262-271.
[6] 李業(yè)森, 張德良, 張現(xiàn)忠等, 18F-AlF-NOTA-G-TMTP1的合成及對(duì)高轉(zhuǎn)移潛能肝癌細(xì)胞荷瘤鼠的顯像研究[J].中華核醫(yī)學(xué)與分子影像雜志, 2015, 35 (5): 351-354.
相似文獻(xiàn)/References:
[1]陳揚(yáng),薩本仲,張韜,等.雙氫青蒿素通過(guò)mTOR信號(hào)通路對(duì)肝癌Hep-G2細(xì)胞凋亡的影響[J].福建醫(yī)藥雜志,2022,44(04):121.
[2]吳嘉旭,胡明超,王強(qiáng),等.NDC1基因在肝癌中的診斷及預(yù)后價(jià)值的生物信息學(xué)分析[J].福建醫(yī)藥雜志,2023,45(01):7.
WU Jiaxu,HU Mingchao,WANG Qiang,et al.Bioinformatics analysis of the diagnostic and prognostic value of NDC1 gene in liver hepatocellular carcinoma[J].FUJIAN MEDICAL JOURNAL,2023,45(05):7.
[3]李業(yè)森.特異性靶向高轉(zhuǎn)移骨肉瘤的長(zhǎng)循環(huán)型PET探針的合成及顯像[J].福建醫(yī)藥雜志,2023,45(06):127.
LI Yesen.Synthesis and imaging of long-circulating PET probes specifically targeting highly metastatic osteosarcoma[J].FUJIAN MEDICAL JOURNAL,2023,45(05):127.